The estimated Net Worth of Catherine Moukheibir is at least $1.07 Millón dollars as of 6 June 2024. Mrs. Moukheibir owns over 80,000 units of Ironwood Pharmaceuticals Inc stock worth over $211,554 and over the last 6 years she sold IRWD stock worth over $517,600. In addition, she makes $338,806 as Independent Director at Ironwood Pharmaceuticals Inc.
Catherine has made over 1 trades of the Ironwood Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 80,000 units of IRWD stock worth $517,600 on 6 June 2024.
The largest trade she's ever made was selling 80,000 units of Ironwood Pharmaceuticals Inc stock on 6 June 2024 worth over $517,600. On average, Catherine trades about 4,706 units every 0 days since 2019. As of 6 June 2024 she still owns at least 48,633 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Mrs. Moukheibir stock trades at the bottom of the page.
Catherine Moukheibir is an Independent Director of the Company. Ms. Moukheibir most recently served as the senior advisor for finance and a member of the executive board at Innate Pharma from March 2011 to December 2016. Prior to that, Ms. Moukheibir was the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. Ms. Moukheibir presently serves on the board of directors of Orphazyme, GenKyoTex, MedDay Pharmaceuticals and Zealand Pharma A/S. She also held past directorships on the boards of Ablynx, Cerenis and Creabilis S.A. Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.
As the Independent Director of Ironwood Pharmaceuticals Inc, the total compensation of Catherine Moukheibir at Ironwood Pharmaceuticals Inc is $338,806. There are 7 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of $10,068,800.
Catherine Moukheibir is 61, she's been the Independent Director of Ironwood Pharmaceuticals Inc since 2019. There are 6 older and 10 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.
Catherine's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts y Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: